Sky Investment Group LLC Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sky Investment Group LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 18,295 shares of the medical research company’s stock after acquiring an additional 223 shares during the period. Thermo Fisher Scientific comprises approximately 1.7% of Sky Investment Group LLC’s investment portfolio, making the stock its 18th largest position. Sky Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $9,104,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Parkside Investments LLC grew its position in Thermo Fisher Scientific by 1.1% in the 1st quarter. Parkside Investments LLC now owns 14,528 shares of the medical research company’s stock valued at $7,229,000 after acquiring an additional 161 shares in the last quarter. Thomasville National Bank grew its position in Thermo Fisher Scientific by 554.1% in the 1st quarter. Thomasville National Bank now owns 19,956 shares of the medical research company’s stock valued at $9,930,000 after acquiring an additional 16,905 shares in the last quarter. Rockland Trust Co. grew its position in Thermo Fisher Scientific by 2.3% in the 1st quarter. Rockland Trust Co. now owns 32,786 shares of the medical research company’s stock valued at $16,314,000 after acquiring an additional 727 shares in the last quarter. Compagnie Lombard Odier SCmA grew its position in Thermo Fisher Scientific by 29.1% in the 1st quarter. Compagnie Lombard Odier SCmA now owns 250,267 shares of the medical research company’s stock valued at $124,533,000 after acquiring an additional 56,371 shares in the last quarter. Finally, Bellecapital International Ltd. grew its position in Thermo Fisher Scientific by 3.0% in the 1st quarter. Bellecapital International Ltd. now owns 13,053 shares of the medical research company’s stock valued at $6,495,000 after acquiring an additional 379 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $414.85 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The stock has a 50 day moving average of $417.11 and a two-hundred day moving average of $493.15. The stock has a market cap of $156.60 billion, a P/E ratio of 25.10, a P/E/G ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 earnings per share. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Analyst Ratings Changes

TMO has been the subject of several research reports. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 23rd. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, April 24th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Finally, Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.